Stock 6785 ALAR PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Alar Pharmaceuticals Inc.

Equities

6785

TW0006785009

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-07-09 pm EDT 		5-day change 1st Jan Change
208.5 TWD -6.92% Intraday chart for Alar Pharmaceuticals Inc. -17.10% -0.48%
May. 10 Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 14 Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Alar Pharmaceuticals Inc is a Taiwan-based company mainly engaged in the research and development of new drugs. The Company mainly develops long-acting drugs for the treatment of opioid use disorder, treatment-resistant depression, and Parkinson disease. The main products include ALA-1000, buprenorphine subcutaneous long-acting sustained-release injection, is indicated for indicated for opioid use disorder (OUD); ALA-1300, subcutaneous injection, is indicated for opioid addiction; ALA-3000, ketamine subcutaneous long-acting sustained-release injection, is indicated for treatment-resistant depression (TRD); ALA-4000, apomorphine subcutaneous long-acting sustained-release injection, is indicated for Parkinson disease (PD); and ALA-2000, subcutaneous injection, is indicated for alcohol addiction and opioid use disorder. The Company distributes ALA-1000 and related products to the United States, France, Germany, the United Kingdom, Italy, and Japan markets.

Number of employees: 22

Sales per Business

TWD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
1 100.0 % 469 100.0 % +58,559.00%

Sales per region

TWD in Million2022Weight2023Weight Delta
United Kingdom
99.8 %
-- 468 99.8 % -
Taiwan
0.2 %
1 100.0 % 1 0.2 % 0.00%

Managers

Managers TitleAgeSince
Yung Shun Wen CEO
 Chief Executive Officer - 16-09-22
Vivian Kang DFI
 Director of Finance/CFO - 19-10-15

Members of the board

Members of the board TitleAgeSince
Charles Lin CHM
 Chairman - 16-09-22
Yung Shun Wen CEO
 Chief Executive Officer - 16-09-22
Cheng Yu Fang BRD
 Director/Board Member - 18-08-06
I Chun Kao BRD
 Director/Board Member - 18-08-06
Shui Sheng Li BRD
 Director/Board Member - 20-07-21
Shu Chin Liang BRD
 Director/Board Member - 20-07-21
Su Fang Yang BRD
 Director/Board Member - 20-07-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,800,000 36,546,000 ( 54.71 %) 0 54.71 %

Company contact information

Alar Pharmaceuticals, Inc.

Room 312 No. 19, Keyuan Road

407 63, Taichung

+

http://www.alarpharm.com
address Alar Pharmaceuticals Inc.(6785)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Specialty & Advanced Pharmaceuticals

Sales per region

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
208.5 TWD
Average target price
290 TWD
Spread / Average Target
+39.09%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
ALAR PHARMACEUTICALS INC. Stock Alar Pharmaceuticals Inc.
-0.48% 427M
MERCK KGAA Stock Merck KGaA
+6.42% 70.2B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+30.84% 10.12B
YUHAN CORPORATION Stock Yuhan Corporation
+29.94% 4.83B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-20.32% 4.53B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+14.99% 3.59B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+20.94% 2.18B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-39.22% 1.8B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-44.28% 1.74B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 6785 Stock
  4. Company Alar Pharmaceuticals Inc.